검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) | Kymriah (tisagenlecleucel) | autologous CD19-directed chimeric antigen receptor (CAR) T-cells |
Overview Company | Kite / Gilead | Novartis | AstraZeneca |
Overview Modality | CGT | CGT | CGT |
Overview Target | CD19 | CD19 | CD19 |
Overview Indication | LBCL, FL | ALL, DLBCL, FL | Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | APPROVED | RECRUITING |
MoA Mechanism | T-cell redirection to CD19+ B cells | CD19-directed CAR T killing | — |
MoA Biomarker | CD19 expression | CD19 | — |
PK/PD Half-life | Expansion peak ~7–14 days | — | — |
PK/PD Species | CAR T expansion, B-cell aplasia | NHP, While of great clinical benefit | — |
PK/PD Animal (cat.) | Unknown | NHP, In vitro | — |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | — |
Toxicology Species | — | NHP, Mouse, While of great clinical benefit | — |
Toxicology Animal (cat.) | Unknown | Mouse | — |
Toxicology Major finding | CRS, ICANS, cytopenias | thrombocytopenia (27%) among 52 responding patients | Cytokine release syndrome after allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide: current understanding and management.. Post-transplant cyclophosphamide (PTCy) is increasingly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (alloHCT), across both haploidentical and HLA-matched donor settings. Howev… |
Toxicology CRS | Grade ≥3 ~13% | 77% | 10% |
Clinical Primary efficacy | ORR 92% | — | ORR 77.3% |
Clinical ORR | 94% | — | 77.3% |
Clinical PFS | 40.2 | — | — |
Clinical OS | NA | 0 | 88 |
Clinical Result source | ClinicalTrials.gov NCT03105336 | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT03642626 |
Clinical Data Tier / Score | S · 100 | B · 69 | C · 65 |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Dose / schedule | One-time IV infusion | Single infusion | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 6일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||
|---|---|---|---|
Overview Program | Yescarta (axicabtagene ciloleucel) | Kymriah (tisagenlecleucel) | autologous CD19-directed chimeric antigen receptor (CAR) T-cells |
Overview Company | Kite / Gilead | Novartis | AstraZeneca |
Overview Modality | CGT | CGT | CGT |
Overview Target | CD19 | CD19 | CD19 |
Overview Indication | LBCL, FL | ALL, DLBCL, FL | Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL |
Overview Phase | APPROVED | APPROVED | PHASE_2 |
Overview Status | APPROVED | APPROVED | RECRUITING |
MoA Mechanism | T-cell redirection to CD19+ B cells | CD19-directed CAR T killing | — |
MoA Biomarker | CD19 expression | CD19 | — |
PK/PD Half-life | Expansion peak ~7–14 days | — | — |
PK/PD Species | CAR T expansion, B-cell aplasia | NHP, While of great clinical benefit | — |
PK/PD Animal (cat.) | Unknown | NHP, In vitro | — |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | — |
Toxicology Species | — | NHP, Mouse, While of great clinical benefit | — |
Toxicology Animal (cat.) | Unknown | Mouse | — |
Toxicology Major finding | CRS, ICANS, cytopenias | thrombocytopenia (27%) among 52 responding patients | Cytokine release syndrome after allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide: current understanding and management.. Post-transplant cyclophosphamide (PTCy) is increasingly used for graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (alloHCT), across both haploidentical and HLA-matched donor settings. Howev… |
Toxicology CRS | Grade ≥3 ~13% | 77% | 10% |
Clinical Primary efficacy | ORR 92% | — | ORR 77.3% |
Clinical ORR | 94% | — | 77.3% |
Clinical PFS | 40.2 | — | — |
Clinical OS | NA | 0 | 88 |
Clinical Result source | ClinicalTrials.gov NCT03105336 | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT03642626 |
Clinical Data Tier / Score | S · 100 | B · 69 | C · 65 |
Clinical Program phase | APPROVED | APPROVED | PHASE_2 |
Clinical Dose / schedule | One-time IV infusion | Single infusion | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 6일 (8일 전) |
추천 비교
추천 비교